Enzalutamide in Biochemically Recurrent Prostate Cancer. Reply
- PMID: 38169498
- DOI: 10.1056/NEJMc2313228
Enzalutamide in Biochemically Recurrent Prostate Cancer. Reply
Comment on
-
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.N Engl J Med. 2023 Oct 19;389(16):1453-1465. doi: 10.1056/NEJMoa2303974. N Engl J Med. 2023. PMID: 37851874 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical